Table 2.

Comparison of clinical data between DRB1*0405 positive and DRB1*0405 negative, DPB1*0402 positive, and DPB1*0402 negative patients

	DRB1*0405 Positive (n=12)	DRB1*0405 Negative (n=140)	P	DPB1*0402 Positive (n=58)	DPB1*0402 Negative (n=94)	P
Male/female	8/4	69/71	0.25	25/33	50/44	0.23
Age at diagnosis (yr)	58 (19–66)	61 (52–68)	0.43	59 (50–67)	63 (52–69)	0.76
MPO-ANCA/PR3-ANCA	1/11	22/118	0.56	47/11	83/11	0.22
GPA/MPA/RLV	0/10/2	44/84/12	0.06	24/32/2	20/62/12	0.01
Muscle pain	3 (25.0)	42 (30.0)	0.72	21 (46.7)	24 (53.3)	0.16
Arthralgia	5 (25.0)	53 (37.9)	0.38	25 (44.6)	31 (55.4)	0.21
Skin rash	1 (8.3)	23 (16.4)	0.46	14 (58.3)	10 (41.7)	0.03
Pulmonary	5 (41.7)	76 (54.3)	0.40	27 (33.3)	54 (66.7)	0.19
Eye	1 (8.3)	33 (23.6)	0.22	12 (35.3)	22 (64.7)	0.70
Ear, nose, and throat	3 (25.0)	57 (40.7)	0.29	27 (45.0)	33 (55.0)	0.16
Gastrointestinal tract	1 (8.3)	18 (12.9)	0.65	8 (42.1)	11 (57.9)	0.71
Nervous system	1 (8.3)	19 (13.6)	0.61	5 (25.0)	15 (75.0)	0.19
Initial serum creatinine (μmol/L)	560 (152–823)	282 (123–596)	0.004	259 (104–596)	314 (135–620)	0.15
Urinary protein (g/24 h)	2 (1.1–3)	2.1 (0.98–3.1)	0.91	2.33 (1.8–2.9)	2.21 (1.3–3.3)	0.44
BVAS	17 (15–20)	20 (16–25)	0.53	20 (15–23)	20 (17–25)	0.98

Data are given as the proportion, median (interquartile range), or n (%). MPO, myeloperoxidase; PR3, proteinase 3; GPA: granulomatosis with polyangiitis (previously nominated as Wegener’s granulomatosis); MPA, microscopic polyangiitis; RLV, renal-limited vasculitis; BVAS, Birmingham Vasculitis Activity Score.